Conclusions
Since the 90% CIs for the test/reference geometric mean ratios for Cmax and AUC0-tlast of Favipiravir are contained within the acceptance limits preset in the Clinical Study Protocol, 80.00-125.00%; according to the applied bioequivalence study, it is concluded that test and reference Favipiravir products are bioequivalent under fasting conditions and test product can be licensed under the requirements of regulatory authorities. Moreover, both study drugs were well-tolerated and considered to be safe.